Synapse - Vincent Miller

Results (270)

Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib

Journal Article

Johnson, M. L.; Riely, G. J.; Rizvi, N. A.; Azzoli, C. G.; Kris, M. G.; Sima, C. S.; Ginsberg, M. S.; Pao, W.; Miller, V. A.
Journal of Thoracic Oncology (2011)

Fulltext@MSK | Save

Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib

Journal Article

Janjigian, Y. Y.; Azzoli, C. G.; Krug, L. M.; Pereira, L. K.; Rizvi, N. A.; Pietanza, M. C.; Kris, M. G.; Ginsberg, M. S.; Pao, W.; Miller, V. A.; more...
Clinical Cancer Research (2011)

Fulltext@MSK | Save

Incidence of EGFR Exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas

Journal Article

D'Angelo, S. P.; Pietanza, M. C.; Johnson, M. L.; Riely, G. J.; Miller, V. A.; Sima, C. S.; Zakowski, M. F.; Rusch, V. W.; Ladanyi, M.; Kris, M. G.
Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

Journal Article

Bivona, T. G.; Hieronymus, H.; Parker, J.; Chang, K.; Taron, M.; Rosell, R.; Moonsamy, P.; Dahlman, K.; Miller, V. A.; Costa, C.; more...
Nature (2011)

Fulltext@MSK | Save

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay

Journal Article

Arcila, M. E.; Oxnard, G. R.; Nafa, K.; Riely, G. J.; Solomon, S. B.; Zakowski, M. F.; Kris, M. G.; Pao, W.; Miller, V. A.; Ladanyi, M.
Clinical Cancer Research (2011)

Fulltext@MSK | Save

A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGER mutations (LUX-Lung 2)

Meeting Abstract

Yang, C.; Shih, J.; Su, W.; Hsia, T.; Tsai, C.; Ou, S. I.; Calvo, R.; Cong, X. J.; Shahidi, M.; Miller, V. A.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Phase II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib

Meeting Abstract

Riely, G. J.; Janjigian, Y. Y.; Azzoli, C. G.; Pietanza, M.; Krug, L. M.; Rizvi, N. A.; Kris, M. G.; Miller, V. A.; Pao, W.; Ginsberg, M. S.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Clinical course of patients (pts) with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKI)

Meeting Abstract

Oxnard, G. R.; Riely, G. J.; Arcila, M. H.; Kris, M. G.; Pao, W.; Ladanyi, M.; Miller, V. A.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

EGFR mutations in men and cigarette smokers with lung adenocarcinoma

Meeting Abstract

Pietanza, M.; D'Angelo, S. P.; Johnson, M. L.; Paik, P. K.; Riely, G. J.; Miller, V. A.; Zakowski, M. F.; Rusch, V. W.; Ladanyi, M.; Kris, M. G.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarinoma: CALGB 30406

Meeting Abstract

Janne, P. A.; Wang, X. F.; Socinski, M. A.; Crawford, J.; Capelletti, M.; Edelman, M. J.; Villalona-Calero, M. A.; Kratzke, R. A.; Vokes, E. E.; Miller, V. A.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save